AR061087A1 - Suspension de hidrogel y su proceso de fabricacion - Google Patents

Suspension de hidrogel y su proceso de fabricacion

Info

Publication number
AR061087A1
AR061087A1 ARP070102025A ARP070102025A AR061087A1 AR 061087 A1 AR061087 A1 AR 061087A1 AR P070102025 A ARP070102025 A AR P070102025A AR P070102025 A ARP070102025 A AR P070102025A AR 061087 A1 AR061087 A1 AR 061087A1
Authority
AR
Argentina
Prior art keywords
suspension
aqueous solution
hydrogel
acidic
manufacturing process
Prior art date
Application number
ARP070102025A
Other languages
English (en)
Inventor
S Hiraoka
T Matsuda
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR061087A1 publication Critical patent/AR061087A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Una suspension de hidrogel que comprende partículas finas y hidroxipropilmetilcelulosa o metilcelulosa de alto peso molecular, que exhibe alta transparencia y estabilidad; y a su proceso de fabricacion. Reivindicacion 3: La suspension de hidrogel de acuerdo con la reivindicacion 1, caracterizada porque la suspension de partículas finas se preparo de una suspension acuosa que se obtiene al mezclar al menos un compuesto seleccionado de polímeros hidrosolubles y agentes tensioactivos, una solucion acuosa ácida o básica, y una solucion acuosa que contiene un compuesto farmacéutico. Reivindicacion 4: La suspension de hidrogel de acuerdo con la reivindicacion 3, caracterizada porque la solucion acuosa ácida o básica es una solucion acuosa ácida, y el compuesto farmacéutico es una sal hidrosoluble de rebamipida.
ARP070102025A 2006-05-12 2007-05-10 Suspension de hidrogel y su proceso de fabricacion AR061087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006133914 2006-05-12

Publications (1)

Publication Number Publication Date
AR061087A1 true AR061087A1 (es) 2008-08-06

Family

ID=38290162

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102025A AR061087A1 (es) 2006-05-12 2007-05-10 Suspension de hidrogel y su proceso de fabricacion

Country Status (13)

Country Link
US (1) US8617606B2 (es)
EP (1) EP2018154B1 (es)
JP (1) JP5203355B2 (es)
KR (1) KR20090014205A (es)
CN (1) CN101442986B (es)
AR (1) AR061087A1 (es)
AT (1) ATE550014T1 (es)
AU (1) AU2007250764A1 (es)
CA (1) CA2649967A1 (es)
ES (1) ES2381285T3 (es)
HK (1) HK1130685A1 (es)
TW (1) TW200808375A (es)
WO (1) WO2007132907A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
DE102010009475B4 (de) * 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
UA114600C2 (uk) * 2011-03-24 2017-07-10 Оцука Фармасьютікал Ко., Лтд. Фармацевтична композиція для лікування захворювання у порожнині рота, що містить ребаміпід
CN102240260B (zh) * 2011-05-17 2012-05-23 山东省医疗器械研究所 一种治疗阴道干涩症的药物及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
CN104082287B (zh) * 2014-07-25 2016-06-22 孙波 一种纤维素基杀菌乳液的制备方法
EP3785716A4 (en) * 2018-04-24 2022-03-02 Shionogi & Co., Ltd SOLID FORMULATION WITH EXCELLENT STABILITY
WO2019208540A1 (ja) 2018-04-24 2019-10-31 塩野義製薬株式会社 安定性に優れた固形製剤
KR101923519B1 (ko) * 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
EP0531529B1 (en) * 1991-03-27 1996-11-20 Senju Pharmaceutical Co., Ltd. Process for preparing aqueous suspension
JP2808378B2 (ja) 1991-03-27 1998-10-08 武田薬品工業株式会社 水性懸濁液剤の製造法
JPH0616556A (ja) * 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
JPH0667853A (ja) 1992-08-17 1994-03-11 Hitachi Ltd 除算器
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
JP2729859B2 (ja) 1993-04-16 1998-03-18 わかもと製薬株式会社 可逆性熱ゲル化水性医薬組成物
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
US20040063678A1 (en) * 1997-10-06 2004-04-01 Bausch & Lomb Incorporated Dexamethasone Gel
DE19744113A1 (de) 1997-10-06 1999-04-15 Mann Gerhard Chem Pharm Fab Dexamethason-Gel
DE10044545A1 (de) * 2000-09-05 2002-04-04 Roland Bodmeier Retardpartikeldispersion
CN1813699B (zh) * 2001-06-14 2012-04-18 大塚制药株式会社 药物组合物
JP2003095924A (ja) 2001-07-16 2003-04-03 Wakamoto Pharmaceut Co Ltd 熱ゲル化人工涙液
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
TW200503709A (en) * 2003-07-17 2005-02-01 Santen Pharmaceutical Co Ltd Itching treating agent containing piperidine derivative as active ingredient
JP5382972B2 (ja) 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
TW200613006A (en) 2004-09-10 2006-05-01 Otsuka Pharma Co Ltd Rebamipide preparation for rectal administration to be prepared before using
WO2006030851A1 (ja) * 2004-09-15 2006-03-23 Santen Pharmaceutical Co., Ltd. ピレノキシン懸濁型点眼剤
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
TWI415629B (zh) 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
JP5186348B2 (ja) 2008-12-05 2013-04-17 アルファー食品株式会社 膨化米飯食品及びその製造方法

Also Published As

Publication number Publication date
ATE550014T1 (de) 2012-04-15
WO2007132907A1 (en) 2007-11-22
KR20090014205A (ko) 2009-02-06
ES2381285T3 (es) 2012-05-24
US20090148529A1 (en) 2009-06-11
US8617606B2 (en) 2013-12-31
CN101442986A (zh) 2009-05-27
CN101442986B (zh) 2011-10-05
AU2007250764A1 (en) 2007-11-22
JP2009536940A (ja) 2009-10-22
CA2649967A1 (en) 2007-11-22
HK1130685A1 (en) 2010-01-08
EP2018154B1 (en) 2012-03-21
TW200808375A (en) 2008-02-16
JP5203355B2 (ja) 2013-06-05
EP2018154A1 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
AR061087A1 (es) Suspension de hidrogel y su proceso de fabricacion
Holder et al. Particle-induced artifacts in the MTT and LDH viability assays
Zhang et al. Pulmonary toxicology assessment of polyethylene terephthalate nanoplastic particles in vitro
Dwivedi et al. Fate of engineered nanoparticles: implications in the environment
BR0315215A (pt) Composições antifúngicas em partìculas sólidas para uso farmacêutico
MY148303A (en) Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
Sha et al. The potential health challenges of TiO2 nanomaterials
Yazdimamaghani et al. Influence of silica nanoparticle density and flow conditions on sedimentation, cell uptake, and cytotoxicity
BRPI0712142A8 (pt) Formulações farmacêuticas para a liberação prolongada de princípio(s) ativo(s), bem como suas aplicações, especialmente aplicações terapêuticas
Sanpui et al. Single-walled carbon nanotubes increase pandemic influenza A H1N1 virus infectivity of lung epithelial cells
ES2422458T3 (es) Procedimiento para la producción de un polvo que contiene carotenoides
DE60335456D1 (de) Absorbierende Artikel enthaltend beschichtete superabsorbierende Partikel
BR112015000017A2 (pt) partículas poliméricas e seu uso
ATE387186T1 (de) Neue zusammensetzungen von sildenafil-freier base
Mantecca et al. Airborne nanoparticle release and toxicological risk from metal-oxide-coated textiles: toward a multiscale safe-by-design approach
WO2007059515A3 (en) Compositions of lipoxygenase inhibitors
TW200624383A (en) Rutile-type titanium oxide ultrafine particle
CL2016001242A1 (es) Suspensiones de partículas de polvos de polímero floculantes y de mezclas de polímero floculantes
DOP2011000329A (es) Preparacion de solido
CY1120585T1 (el) Εναιωρηματα νανοσωματιδιων που περιεχουν πολυμερες καρβοξυβινυλιου
CY1113825T1 (el) Υδατικα εναιωρηματα ριλουζολης
DE602005025082D1 (de) Nicht-lamellare zubereitungen von dioleoyl-phosphatidyl ethanolamin und polysorbat80
BRPI0505279A (pt) composição de toner
TW200711719A (en) Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants
WO2009007992A8 (en) Pharmaceutical composition produced by microprecipitation

Legal Events

Date Code Title Description
FB Suspension of granting procedure